Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 2529 entries
View as:

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01402440 Org: User:
Start: 11/30/11 End: 04/30/14 Due: 04/30/15

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04816214 Org: User:
Start: 09/22/21 End: 12/27/22 Due: 12/27/23

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT04179175 Org: User:
Start: 03/18/20 End: 07/15/26 Due: 07/15/27

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Phase: N/A Priority: Normal
NCT ID: NCT01919229 Org: User:
Start: 10/31/13 End: 09/30/14 Due: 09/30/15

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT02867735 Org: User:
Start: 09/21/16 End: 02/15/18 Due: 02/15/19

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Phase: N/A Priority: Normal
NCT ID: NCT00466063 Org: User:
Start: 05/31/07 End: 07/31/15 Due: 07/31/16

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02551224 Org: User:
Start: 09/30/15 End: 03/31/16 Due: 03/31/17

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02404441 Org: User:
Start: 04/27/15 End: 07/21/20 Due: 07/21/21

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase: N/A Priority: Normal
NCT ID: NCT02040870 Org: User:
Start: 03/07/14 End: 07/27/17 Due: 07/27/18

Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00420485 Org: User:
Start: 03/31/06 End: 11/30/10 Due: 11/30/11

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Phase: N/A Priority: Normal
NCT ID: NCT01402401 Org: User:
Start: 11/30/11 End: 06/30/13 Due: 06/30/14

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00427999 Org: User:
Start: 02/28/07 End: 08/31/15 Due: 08/31/16

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT01179737 Org: User:
Start: 07/31/10 End: 01/31/13 Due: 01/31/14

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00081926 Org: User:
Start: 10/31/03 End: 03/31/07 Due: 03/31/08

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01846468 Org: User:
Start: 03/01/13 End: 06/28/14 Due: 06/28/15

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Phase: N/A Priority: Normal
NCT ID: NCT05507437 Org: User:
Start: 11/22/22 End: 04/25/24 Due: 04/25/25

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01169844 Org: User:
Start: 06/30/10 End: 11/30/12 Due: 11/30/13

Revolade Tablets Specified Drug-use Survey

Phase: N/A Priority: Normal
NCT ID: NCT06287268 Org: User:
Start: 07/17/24 End: 03/28/29 Due: 03/28/30

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT04641442 Org: User:
Start: 12/18/20 End: 11/14/27 Due: 11/14/28

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00980018 Org: User:
Start: 12/31/09 End: 12/31/12 Due: 12/31/13

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

Phase: N/A Priority: Normal
NCT ID: NCT00306787 Org: User:
Start: 03/31/06 End: 02/29/08 Due: 02/28/09

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT05285904 Org: User:
Start: 05/12/22 End: 06/30/26 Due: 06/30/27

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01529294 Org: User:
Start: 08/31/10 End: 07/31/12 Due: 07/31/13

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Phase: N/A Priority: Normal
NCT ID: NCT00237185 Org: User:
Start: 06/30/00 End: 06/30/13 Due: 06/30/14

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Phase: N/A Priority: Normal
NCT ID: NCT03386474 Org: User:
Start: 01/15/18 End: 09/06/18 Due: 09/06/19